Estuary Biotherapeutics develops locally delivered AAV gene therapies for patients with serious kidney disease, starting with treatments intended to address the genetic causes of autosomal dominant polycystic kidney disease (ADPKD).

Founders

• Michael Caplan · co-founder; C.N.H. Long Professor and Chair of Cellular and Molecular Physiology, Yale School of Medicine
• Stefan Somlo · co-founder; C.N.H. Long Professor of Medicine and Genetics and Professor of Nephrology, Yale School of Medicine
• Xavier Anguela · co-founder; Vice President, Gene Therapy, Eli Lilly
  Before and alongside Estuary, he held scientific leadership roles at Nava Therapeutics, AskBio and Spark Therapeutics, and is Vice President of Gene Therapy at Eli Lilly.
• Wayne Sackett · CEO and co-founder
  Before founding Estuary, he worked at MyoKardia from 2015 until Bristol Myers Squibb acquired it in 2020, ultimately serving as Head of Business Development and Corporate Strategy; he holds an MBA from Harvard Business School and a BS with honors in chemical engineering from the University of California, Berkeley.

Total raised

$103 million · as its sources put it, more than the rounds on record

Competitors

Regulus Therapeutics, Renasant Bio